Journal of Bioequivalence & Bioavailability

Iyer K

Publications

• Research Article
  Bioequivalence of Two Different Rivastigmine Hard Capsule Formulations of Two Different Strengths (1.5 mg and 6 mg) in Indian Healthy Human Adult Male Volunteers
  Author(s): Garg M, Naidu R, Iyer K and Jadhav RGarg M, Naidu R, Iyer K and Jadhav R
  
  Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of Alzheimer's disease (AD). The aim of these studies was to determine the bioequivalence of test and reference formulations of Rivastigmine 1.5 mg and 6 mg Hard Capsule. Both studies were single dose, randomized, 2-period, 2-sequence, laboratory-blinded, crossover design. Rivastigmine 1.5 mg Hard Capsule study was conducted in 36 healthy adult Indian male volunteers under fasting conditions with a washout period of 5 days and Rivastigmine 6 mg Hard Capsule study was conducted in 40 healthy adult Indian male volunteers under fed conditions with a washout period of 7 days. For 1.5 mg study, blood samples for pharmacokinetic profiling were taken post-dose up to 10 h. For 6 mg study, blood samples for pharmacokinetic profiling were taken post-dose up to 12 h. Safe.. View More»
  DOI: 10.4172/jbb.1000317

  Abstract PDF